Selexis’ proprietary SUREtechnology Platform facilitates the rapid, stable, and cost-effective production of virtually any recombinant protein and provides seamless integration of the biologics dev...
Under the agreement, Progenics will have use of the Selexis CHO-M Cell Line™ and the SUREtechnology Platform™ for the development, manufacture, and commercialization of Progenics’ prostate specific...
Under the agreement, Liomont will have use of the Selexis CHO-M Cell Line™ and the SUREtechnology Platform for the development, manufacture and commercialization of an undisclosed antibody.
Receive JSR Life Sciences news on your RSS reader.